Thursday, 17 Aug 2017

Biologic/Novel Rx

Date Typesort ascending Title Save
14 Apr 2017 Social How will new BIOSIMILAR biologic drugs affect PATIENTS - Make Your views count in a Patient survey; vote at>> https://t.co/ZhM9MiDCd7
08 Jun 2016 Social Is there enough data to support a non-TNFi biologic as the 1st choice? Dr. Janet Pope says the data clearly says so https://t.co/Ai5izsTDN8
10 May 2017 Social Responses to Orencia may be dependent on baseline memory B cells (CD38+ CD27+) https://t.co/zro040Y54W
23 Oct 2015 Social Pretreatment CRP or IL-6 levels are not predictive of responses to tocilizumab https://t.co/IOQGWOGGQA
16 Nov 2016 Social RT @rachelthuston: TCZ for clinical remission in GCA but doesn't fully suppress MR signals of vessel inflammation #ACR16 @RheumNow https://…
16 Jan 2017 Social Baricitinib decision by the FDA extended from Jan 2017 by another 3 mos for FDA to review major amendment to NDA https://t.co/tMi3llwWZw
17 Jun 2015 Social Metanalysis of 7 RCTs compares high vs low dose RTX in RA shows little clinical difference. Better Xray w/ high dose http://t.co/ySSo3gVKE8
23 May 2017 Social FDA approves Actemra as1st approved drug to treat Giant Cell Arteritis. See RheumNow report. https://t.co/73UieZpbn1 https://t.co/HjUzi0H6OL
27 Nov 2015 Social RCT shows Hidradenitis suppurativa pts respond well to anakinra (esp after wk 8) w/ less IFN and increased IL-22 https://t.co/OfndT569gt
15 Feb 2017 Social Correction: Abbvies JAK inhibitor ABT-494) has a name, Uptacitinib, is currently in phIII trials. #RWCS 2017 info from Dr. M Genovese
06 Aug 2017 Social RheumNow Wk in Review is up! FDA hearings on sirukumab, tofacitinib. iTUNES, podcast https://t.co/rX1zLRHUuA & video https://t.co/slvfTJYR1E
25 Feb 2016 Social How to manage patients who worry, wont do & negatively inclined re:health/meds - the negative narrator in your head https://t.co/KEeVcWVedr
13 Mar 2017 Social Review of severe alopecia areata 90pts Rx w/ Xeljanz: 20% nearly total regrowth, 58% >50% regrowth,77% some regrowth https://t.co/8BZwOqevct
22 Sep 2015 Social OCTAVE studies shows tofacitinib 10 mg bid to be effective in treating moderate to severe ulcerative colitis http://t.co/MbdSUymAji
15 Apr 2016 Social Tocilizumab to remain a second line treatment for polymyalgia rheumatica. More RCT needed https://t.co/yPcFI9s3CR @DrPetryna
06 May 2016 Social A FREE Patient Guide to Biologic Use - available now at the RheumNow Website. 13 pages jammed with Patient Education https://t.co/f4BJvLu84N
02 May 2015 Social Are you Biosimilar Bonkers? Heres as collection of Reports, forecasts etc. http://buff.ly/1AtJ593 
21 Apr 2017 Social Small study of 13 alopecia pts (2 totalis, 7universalis); Xeljanz Rx 7/13 had >50% regrowth w/in 9 mos, 2 d/c https://t.co/w5OxVvdIvQ
29 Nov 2016 Social Good, basic overview of Biosimilars. https://t.co/N0hE8xL8Ga
31 Jan 2017 Social @jhoronjeff @pfizer @US_FDA You missed the point - this is the kind of study that must be done to get an interchangeability indication